TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05429281

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates-based Core Strengthening Exercises
Description: The PsCS group performed eight Pilates exercises over 45 minutes, three times per week for 12 successive weeks. The training was conducted under the supervision of a physical therapist who had more than 5 years of experience in Pilates.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plyometric-based Muscle Loading Exercises
Description: The PlyoML group performed 10 plyometric exercises over 45 minutes, three times per week for 12 successive weeks. The training was conducted under the close supervision of a licensed pediatric physical therapist. The safety and performance guidelines, defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association, were considered during training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Pilates and Plyometrics
Description: The combined training group performed the same exercises as the PsCS and PlyoML groups, although with half the number of sets/repetitions over 45 minutes, three times per week for 12 successive weeks. The PsCS and PlyoML were executed within the same session, with a 10-to-15-minute rest interval. The training was conducted under the close supervision of a licensed pediatric physical therapist. The safety and performance guidelines, defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association, were considered during training.
Study: NCT04984018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide + camrelizumab
Description: Pts received 200 mg camrelizumab intravenously every 2 weeks and Chidamide 30mg orally twice (biw) per week for 4 consecutive weeks every 6 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
Study: NCT05291143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short videos on blood pressure monitoring
Description: Short videos on blood pressure monitoring
Study: NCT04777630

Intervention type: DIAGNOSTIC_TEST
Intervention: None, neuroimaging
Description: Observation only to observe differences in neuroimaging

Intervention type: DIAGNOSTIC_TEST
Intervention: None, neuroimaging
Description: Observation only to observe differences in neuroimaging
Study: NCT05624177

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Streptococcus salivarius M18 probiotic 1 billion colony forming units chewing gum (chew 5 minutes)
Description: Probiotic Streptococcus salivarius M18 products are commercially available in traditional formats such as a chewable tablet (lozenge) for local delivery to the oral cavity to provide health benefits. In this study, a chewing gum formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Streptococcus salivarius M18 probiotic 1 billion colony forming units chewing gum (chew 10 minutes)
Description: Probiotic Streptococcus salivarius M18 products are commercially available in traditional formats such as a chewable tablet (lozenge) for local delivery to the oral cavity to provide health benefits. In this study, a chewing gum formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
Study: NCT06065462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-100
Description: GIven by vein (IV)
Study: NCT06381089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Rehabilitation
Description: Lokomat is an exoskeleton type robotic walking device that can support both extremities symmetrically.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Rehabilitation
Description: Lokomat is an exoskeleton type robotic walking device that can support both extremities symmetrically.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagal Nerve Stimulation
Description: Vagus nerve stimulation is defined as any technique that stimulates the vagus nerve in our body.
Study: NCT06144216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLOE Outreach Intervention
Description: The CLOE outreach intervention is a community-led, strengths-based, and trauma-informed program to support self-identifying women and youth who experience interpersonal and structural gender-based violence. Outreach services are designed to mitigate the effects of gender-based violence, build trusting relationships with service providers, and improve safety, well-being and engagement with health and social care.
Study: NCT05584735

Intervention type: BIOLOGICAL
Intervention: Influenza vaccine
Description: Observe effects of flu vaccine on microbiome

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Observe effects of COVID-19 vaccine on microbiome
Study: NCT05356520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy Ivor-lewis
Description: Endoscopy Ivor-lewis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic transabdominal enlarged gastrectomy
Description: Laparoscopic transabdominal enlarged gastrectomy
Study: NCT04224779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: The biological collection will include samples of blood samples collected at different times but also tumoral biopsy before the surgery.
Study: NCT04208516

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Erector Spinae Plane Nerve Block
Description: To be administered to subjects in the active comparator group receiving primary unilateral thoracic surgery.
Study: NCT06428123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy on present Lower Limb
Description: Patients will be seated close to a table on which a mirror will placed vertically. The normal (i.e., no amputated limb) will be placed in front of the mirror and made to perform movements of the different joints while the patient looking into the mirror.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mental Imagery on present Lower Limb
Description: Mental imagery technique in which patients will be instructed to concentrate on sensations from each area of the body, including the phantom limb. Patients will be advised to imagine comfortable, thorough movement and sensation in the phantom limb, such that they could stretch away the pain, and finally to allow the limb to rest in a comfortable position. The actual therapy of moving and feeling the limb will lasted for 5 minutes. Patients will be asked to perform 40 minutes of meditation and imagery exercises.
Study: NCT05680246

Intervention type: DEVICE
Intervention: DHOPE-PRO
Description: Prolonged DHOPE preservation \>4 hours
Study: NCT06463470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)
Description: CBT-AR describes an adaption of cognitive behavioural therapy for use with individuals diagnosed with Avoidant/Restrictive Food Intake Disorder (ARFID).
Study: NCT05401500

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sampling
Study: NCT04208516

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Quadratus Lumborum Nerve Block
Description: To be administered to subjects in the active comparator group receiving primary major abdominal surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Erector Spinae Plane Nerve Block
Description: To be administered to subjects in the experimental group receiving primary unilateral thoracic surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Quadratus Lumborum Nerve Block
Description: To be administered to subjects in the experimental group receiving primary major abdominal surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: To be given postoperatively as a continuous infusion at a dose of 50 mg/hr in the experimental group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: To be used in both treatment arms as nerve block initial bolus injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: To be used in both treatment arms as nerve block initial bolus injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: To be used in the experimental arm as a nerve block adjuvant to promote prolonged single block duration, as is standard of care in this institution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: To be used in the experimental arm as a nerve block adjuvant to promote prolonged single block duration, as is standard of care in this institution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: To be used perineurally as a 0.25% solution in the active comparator group at a rate of 10 ml/hr per perineural catheter.
Study: NCT05959109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peresolimab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peresolimab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peresolimab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peresolimab
Description: Administered SC
Study: NCT06143488

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular therapy
Description: Drug: Best medical management All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.~Procedure: Endovascular therapy In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Description: Drug: Best medical management All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.~Procedure: Endovascular therapy In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best medical management
Description: All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
Study: NCT06135285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control subjects
Description: The subject will be repositioned from the prone to recovery position
Study: NCT06103526

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Immunonutrition
Description: enteral supplementation with high amount of proteins, arginine, glutamine, nonessential fatty acids, branched chain fatty acids, nucleotides, or RNA
Study: NCT05144620

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D Mapping
Description: 3D model will be made from diagnostic imaging for pre-surgical planning
Study: NCT05287659

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: meal replacements or supplementation with leucine
Description: meal replacements or animal protein or supplementation with leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: meal replacements or supplementation with leucine
Description: meal replacements or animal protein or supplementation with leucine
Study: NCT06577051

Intervention type: DIAGNOSTIC_TEST
Intervention: Eustachian tube function test with 226 and 1000 Hz probes
Description: In children undergoing tonsillectomy ± adenoidectomy without eustachian dysfunction, tympanometry with 226 Hz and 1000 Hz probes, ipsi and contralateral acoustic reflexes with 226 Hz probe, eustachian function test with 226 Hz probe (automatic Williams test) and play audiometry in young children and pure tone audiometry in older children are aimed to control tubal functions in preoperative period, postoperative day 1 and week 2.
Study: NCT05287659

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: meal replacements or supplementation with leucine
Description: meal replacements or animal protein or supplementation with leucine
Study: NCT05763628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens (stenfilcon A)
Description: Daily Disposable Multifocal Contact Lens for 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens (stenfilcon A)
Description: Daily Disposable Multifocal Contact Lens for 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens (senofilcon A)
Description: Daily Disposable Multifocal Contact Lens for 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens (senofilcon A)
Description: Daily Disposable Multifocal Contact Lens for 2 weeks
Study: NCT05853679

Intervention type: DEVICE
Group type: OTHER
Intervention: Lumoral Treatment
Description: The device will be used 5 to 7 times per week according to the manufacturer's instructions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumoral Treatment
Description: The device will be used 5 to 7 times per week according to the manufacturer's instructions.
Study: NCT05946083

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin Intervention
Description: For 6 weeks, 23 binge drinkers will be given a daily dose (divided into three times a day) of 15g of a dietary fiber with benefits for intestinal bacteria (inulin).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin Intervention
Description: For 6 weeks, 23 binge drinkers will be given a daily dose (divided into three times a day) of 15g of dietary fiber with no specific benefits for the intestinal microbiome (maltodextrin).
Study: NCT05853679

Intervention type: OTHER
Group type: OTHER
Intervention: Standard oral hygiene instructions according to the Finnish Dental Association
Description: Participants will be instructed to clean their teeth twice per day by an electric toothbrush, an interdental brush, and flossing.
Study: NCT06001788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral administration
Study: NCT06580444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brexanolone
Description: The participant will receive either a placebo, or 90, 60, or 30 mcg/kg/hr of Brexanolone over a 20-hour period intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brexanolone
Description: The participant will receive either a placebo, or 90, 60, or 30 mcg/kg/hr of Brexanolone over a 20-hour period intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brexanolone
Description: The participant will receive either a placebo, or 90, 60, or 30 mcg/kg/hr of Brexanolone over a 20-hour period intravenous infusion.
Study: NCT06578975

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HT-ENDO-MOS-A13
Description: Mutli-Omics based biomarker to diagnose primary hypertension or endocrine forms of hypertension; primary aldosteronism, pheochromocytoma/functional paraganglioma or Cushing syndrome.

Intervention type: OTHER
Group type: OTHER
Intervention: Normal diagnosis
Description: Standard diagnosis for endocrine hypertension
Study: NCT05338099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN001
Description: EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10\^5 cells/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN001
Description: EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.~Dose group B (High dose): 2.5x10\^6 cells/kg
Study: NCT06001788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Description: Subcutaneous injection
Study: NCT06156072

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound-guided venipuncture
Description: Venipuncture will be performed using ultrasound to identify the most appropriate vessel and guide the puncture
Study: NCT05350241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Split-belt treadmill training
Description: Participants in the split-belt walking group (experimental group) performed repeated split-belt treadmill training with an error-augmentation strategy (exaggeration of the initial step-length asymmetry) for 60 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: Participants in the control group received the standard physical therapy program. Each session lasted for 60 minutes, repeated three times a week, over 12 consecutive weeks. The program consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
Study: NCT05199818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron HCl Buccal Film 0.5 mg
Description: Palonosetron HCl Buccal Film and IV palonosetron placebo, both administered on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Palonosetron 0.25 mg
Description: IV Palonosetron and Palonosetron HCl Buccal Film placebo, both administered on Day 1
Study: NCT06434545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Reasoning methodology
Description: Twenty nursing teams will be trained in the Palliative Reasoning methodology during a four hour training, split into two sessions. Additionally, teams receive a coaching session ones a month and practice with a real life case every week or two weeks during a one hour team meeting. This will be compared with 20 other nursing teams that will continue to provide care as usual.
Study: NCT02988245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Geneticure Panel for HTN therapy
Description: Using either Genetics (Geneticure for HTN multi-gene panel) or JNC-8 guidelines for prescribing for patients with hypertension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNC-8
Description: Using JNC-8 guidelines to guide therapy
Study: NCT05288010

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Cannabis
Description: The provision of whole flower cannabis via an inhalation device in addition to standard of care chronic pain treatment.
Study: NCT04949659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Description: Laparoscopic appendectomy performed with defined, randomized to level of pressure for pneumoperitoneum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Description: Laparoscopic appendectomy performed with defined, randomized to level of pressure for pneumoperitoneum
Study: NCT06537141

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: selective embolization of thyroid arteries (SETA)
Description: selective embolization of thyroid arteries
Study: NCT04811261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Infusion of UCLSCs
Description: The first 3 subjects will be administered 50 x 10\^6 ULSCs reconstituted in PBS with 1% human serum albumin in a volume of 250 ml, and monitored for adverse events or toxicities, immediately following dosing, and again at 30 days.
Study: NCT06384417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hello for Cancer game
Description: To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').~The questions used in Hello for Cancer were modified from the original Hello game based on the results of phase 1 of testing this game in cancer populations. The modifications made to the game will be assessed for acceptability during this study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Table Topics game
Description: To play Table Topics, players are provided a deck of cards that have a variety of general conversation starter questions. The group takes turns selecting a card and reading it to the group for the group to answer. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').